Buprenorphine Patch, Extended Release
Product Images NDC 3215-1521

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Buprenorphine (NDC 3215-1521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aveva Drug Delivery Systems Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Fig1 Slc 0054)

This text provides a description of a drug delivery system with layers including a backing layer, overlapping adhesive film, separating layer, drug/polymer adhesive matrix, and a peakoff release liner. Each layer plays a specific role in delivering the drug effectively and efficiently.*

FDA Label Image

Fig2 (Fig2 Slc 0054)

This text provides data on the concentration of Buprenorphine Transdermal System (TDS) at 10 mcg/hour administered every 7 days for a total of 3 doses, with a sample size of 36. The concentration level is measured in picograms per milliliter (pg/mL) over a span of 26 days. The graph shows the change in concentration over time for the Buprenorphine TDS.*

FDA Label Image

Fig3 (Fig3 Slc 0054)

This is a measurement table showing the percent of reduction or improvement in pain for patients taking either a placebo or Buprenorphine TOS 10/20. The table indicates the results in increments from 0% to 100%.*

FDA Label Image

Fig4 (Fig4 Slc 0054)

This text provides information on Buprenorphine TDS 5 and Buprenorphine TDS 20, along with the percentage of patients improved and the percent of reduction/improvement in pain. The data is structured in a tabulated format, showing the different percentages of improvement and reduction in pain.*

FDA Label Image

Image Description (Figa Slc 0054)

FDA Label Image

Image Description (Figb Slc 0054)

FDA Label Image

Image Description (Figc Slc 0054)

FDA Label Image

Image Description (Figd Slc 0054)

FDA Label Image

Image Description (Fige Slc 0054)

This appears to be a description of a figure labeled as "Figure E" with a foil backing, patch, and a foil handle. This suggests the presence of a product or material that involves a foil-based construction with specific features like a patch and handle.*

FDA Label Image

Image Description (Figf Slc 0054)

FDA Label Image

Image Description (Figg Slc 0054)

FDA Label Image

Image Description (Figh Slc 0054)

FDA Label Image

Image Description (Figi Slc 0054)

FDA Label Image

Image Description (Figj Slc 0054)

FDA Label Image

Image Description (Figk Slc 0054)

FDA Label Image

Image Description (Figl Slc 0054)

FDA Label Image

Image Description (Figm Slc 0054)

FDA Label Image

Image Description (Fign Slc 0054)

FDA Label Image

Image Description (Figo Slc 0054)

FDA Label Image

Carton-7.5mcg (Image002)

FDA Label Image

Carton-10mcg (Image003)

FDA Label Image

Carton-5mcg (Image01)

FDA Label Image

Carton-15mcg (Image04)

FDA Label Image

Carton-20mcg (Image05)

Description not available.*

FDA Label Image

Structure (Structure Slc 0054)

FDA Label Image

Image Description (Table1 Slc 0054)

This text provides information on the recommended starting doses for Buprenorphine Transdermal System based on the previous opioid analgesic daily dose in oral morphine equivalent. The starting doses are 5 mcg/hour for a daily dose of <30 mg and 10 mcg/hour for a daily dose of 30-80 mg.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.